4-[4-(imidazol-2-yl)phenoxy]aniline | 1228885-79-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4-(imidazol-2-yl)phenoxy]aniline
• 英文别名: 4-[4-(1H-imidazol-2-yl)phenoxy]aniline
• CAS: 1228885-79-7
• 化学式: C₁₅H₁₃N₃O
• 分子量: 251.288
• InChiKey: HIKSXNYETJNKAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[4-(imidazol-2-yl)phenoxy]aniline 、 N,N'-羰基二咪唑 以 四氢呋喃 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives

  摘要：

  Two series of novel diaryl ureas have been designed and synthesized, with their in vitro antitumor effect screened on human non-small cell lung cancer (NSCLC) cell line A549 and human breast cancer cell line MDA-MB-231. Some target compounds demonstrated significant inhibitory activities against both cell lines. Compared to contrast drug Sorafenib, 1b, 1d, 1f, 1i were found to demonstrate more potent antitumor activities. The structures of all the newly synthesized compounds were determined by (1)H, (13)C NMR, MS, IR and elementary analysis.

  DOI：

  10.1016/j.ejmech.2010.02.005
• 作为产物：
  描述：

  2-[4-(4-nitrophenoxy)phenyl]imidazole 在 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以87%的产率得到4-[4-(imidazol-2-yl)phenoxy]aniline
  参考文献：
  名称：

  Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives

  摘要：

  Two series of novel diaryl ureas have been designed and synthesized, with their in vitro antitumor effect screened on human non-small cell lung cancer (NSCLC) cell line A549 and human breast cancer cell line MDA-MB-231. Some target compounds demonstrated significant inhibitory activities against both cell lines. Compared to contrast drug Sorafenib, 1b, 1d, 1f, 1i were found to demonstrate more potent antitumor activities. The structures of all the newly synthesized compounds were determined by (1)H, (13)C NMR, MS, IR and elementary analysis.

  DOI：

  10.1016/j.ejmech.2010.02.005

文献信息

• [EN] INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS<br/>[FR] INHIBITEURS DE LA VOIE DE SIGNALISATION NOTCH ET LEUR UTILISATION DANS LE TRAITEMENT DE CANCERS
  申请人：CELLESTIA BIOTECH AG

  公开号：WO2020208139A1

  公开（公告）日：2020-10-15

  The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.

  本发明涉及新的Notch信号通路抑制剂及其在治疗和/或预防癌症中的应用。
• INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS
  申请人：Cellestia Biotech AG

  公开号：EP3953335A1

  公开（公告）日：2022-02-16
• COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF
  申请人：Cellestia Biotech AG

  公开号：US20220169642A1

  公开（公告）日：2022-06-02

  The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.
• Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives
  作者：Min Sun、Xiaoqing Wu、Junqing Chen、Jin Cai、Meng Cao、Min Ji

  DOI：10.1016/j.ejmech.2010.02.005

  日期：2010.6

  Two series of novel diaryl ureas have been designed and synthesized, with their in vitro antitumor effect screened on human non-small cell lung cancer (NSCLC) cell line A549 and human breast cancer cell line MDA-MB-231. Some target compounds demonstrated significant inhibitory activities against both cell lines. Compared to contrast drug Sorafenib, 1b, 1d, 1f, 1i were found to demonstrate more potent antitumor activities. The structures of all the newly synthesized compounds were determined by (1)H, (13)C NMR, MS, IR and elementary analysis.